New Treatment for psoriasis: therapeutic efficiency in patients and antiinflammatory effect in vitro

Abstract

Background: Psoriasis is a worldwide chronic inflammatory disease that is increasingly being considered as a systemic disorder. Antioxidant and anti-inflammatory molecules have been revealed as potential adjuvants for traditional therapies.Objectives: To evaluate the antiinflammatory action of selected antioxidant molecules and their beneficial effect as combination therapy in psoriatic patients. Materials & Methods: Thirty-five patients with mild (five), moderate (nine) and severe (twenty one) psoriasis were selected and treated with EP2311454 treatment. PASI, BSA and DLQI assessed the severity of psoriasis and the impact on quality of life. The antiinflammatory effect was tested in IFN-γ stimulated Raw264.7 macrophages that express human PPARG.Results: The combined use in vitro of several EP2311454 components exerts a synergistic inhibitory effect on the expression of the proinflammatory mediators Cox2, Nos2 and Cxcl9. Clinically, more than 80% reduction in DLQI levels is observed after treatment, and 100% of severe patients achieved PASI 75 and significant reduction of BSA levels after 15 days of treatment.Conclusion: EP2311454 treatment, composed by antioxidant molecules, proved to be antiinflammatory in vitro and showed efficacy in patients with mild to severe psoriasis, as demonstrated by a significant decrease in PASI, BSA and DLQI levels.